Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMN 110 (elosulfase alfa) in MPS IVA (Morquio A)
NCT00884949Phase 2Completed
- Sponsor
- BioMarin Pharmaceutical
- Start
- Apr 2009
- Primary completion
- Feb 2011
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of elosulfase alfa in Mucopolysaccharidosis type IV A, sponsored by BioMarin Pharmaceutical. Primary endpoint: Subject Incidence of Treatment Emergent Adverse Events at Week 84. Started Apr 2009; status: completed.
02
Drugs
elosulfase alfa
03
Conditions
Mucopolysaccharidosis type IV A
Beyond the preview
Go deeper on NCT00884949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00884949.